UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?

Biogen (BIIB) stock got an upgrade to Buy from UBS with a $225 price target, citing upcoming BIIB080 tau and litifilimab Phase 3 data as major catalysts over the next 12-15 months.

Biogen trades at a 13x forward P/E—a notable discount to peers—and the market may not yet be pricing in the pipeline readouts expected this summer and in Q4 2026.

The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.

Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the stock to Buy from Neutral and raised his price target to $225 from $185. The call centers on a specific sequence of pipeline readouts Yee believes can move the stock meaningfully higher heading into 2027. This follows Monday’s Wells Fargo upgrade, signaling that Wall Street is increasingly constructive on Biogen’s near-term story.

Biogen shares traded at $192 Wednesday morning, up 3% on the day. The stock has gained 62% over the past year, yet UBS argues it remains an “under-owned out-of-favor stock that trades at a discount to large-cap peers” with a compelling catalyst runway ahead.

Ticker

Company

Firm

Action

Old Rating

New Rating

Old Target

New Target

BIIB

Biogen

UBS

Upgrade

Neutral

Buy

$185

$225

UBS has increased conviction on Biogen’s pipeline based on a concentrated window of catalysts arriving over the next 12 to 15 months. Yee specifically points to BIIB080 tau data expected this summer as a near-term upside driver, followed by the “real upside catalyst”: Phase 3 litifilimab data in systemic lupus expected in Q4 2026. Litifilimab already holds FDA Breakthrough Therapy Designation for cutaneous lupus, adding regulatory credibility to the program.

READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks

The FDA granted Priority Review for LEQEMBI IQLIK, a subcutaneous formulation, with a PDUFA date of May 24. Approval would improve patient convenience and potentially accelerate uptake of Biogen’s Alzheimer’s franchise, which posted $134 million in global in-market sales in Q4 2025, up 54% year over year.

Biogen is a Cambridge, Massachusetts-based biopharma company focused on neurological and rare diseases. Its legacy multiple sclerosis franchise generated $917 million in Q4 2025 revenue, down 14% year over year, putting pressure on total revenue. Growth products, including LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, combined for $1 billion in revenue for full year 2025, up 19% for the year. Biogen ended Q4 with $3.009 billion in cash and generated $2.051 billion in free cash flow for the full year.

The UBS upgrade arrives as Biogen trades at a forward P/E ratio of 13x, a notable discount relative to large-cap biopharma peers. CEO Christopher Viehbacher has described the pipeline as a multi-year data flow, noting “10 additional potentially registrational studies across our pipeline expected to read out sequentially over the next four years.” UBS’s thesis is that the market hasn’t yet priced in the Q4 litifilimab readout or the BIIB080 tau data, creating a setup where the next 12 months could be a genuine re-rating event.

Two Wall Street firms upgrading Biogen within 48 hours is a signal worth taking seriously, even if the theses differ. Wells Fargo emphasized franchise diversification; UBS is focused on specific, time-stamped catalysts. If you’re considering Biogen stock, the key question is whether you believe the litifilimab Phase 3 data in Q4 and BIIB080 results this summer will surprise to the upside.

The risks are real. Biogen’s total revenue is expected to decline mid-single digits in 2026, and the MS franchise continues to erode. Investors comfortable with binary catalyst risk and a longer time horizon may find the valuation compelling at current levels. Those who prefer steadier fundamentals may want to wait for the LEQEMBI IQLIK decision in May before adding exposure.

Wall Street is pouring billions into AI, but most investors are buying the wrong stocks. The analyst who first identified NVIDIA as a buy back in 2010 — before its 28,000% run — has just pinpointed 10 new AI companies he believes could deliver outsized returns from here. One dominates a $100 billion equipment market. Another is solving the single biggest bottleneck holding back AI data centers. A third is a pure-play on an optical networking market set to quadruple. Most investors haven’t heard of half these names. Get the free list of all 10 stocks here.